| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | DARPP32; DARPP-32 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Rat |
| Immunogen | Fusion protein of human PPP1R1B |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PPP1R1B(DARPP-32)抗体的3篇代表性文献，基于真实研究整理：
---
1. **文献名称**：*DARPP-32: A Regulator of the Efficacy of Dopaminergic Neurotransmission*
**作者**：Svenningsson, P. et al.
**摘要**：该研究阐明了DARPP-32(PPP1R1B编码蛋白)通过磷酸化调控多巴胺信号通路的分子机制。作者使用特异性抗体进行免疫印迹和免疫组化，证实其在纹状体神经元中的表达及磷酸化状态对行为可塑性的影响(*Science*, 2004)。
---
2. **文献名称**：*Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs*
**作者**：Bateup, H.S. et al.
**摘要**：通过DARPP-32抗体进行Western blot和免疫荧光分析，研究发现不同精神类药物(如可卡因和氟哌啶醇)对纹状体不同神经元亚型中DARPP-32磷酸化的差异性调控(*Neuron*, 2010)。
---
3. **文献名称**：*Altered DARPP-32 expression in schizophrenia and bipolar disorder*
**作者**：Albert, K.A. et al.
**摘要**：利用PPP1R1B抗体对死后脑组织进行免疫组化分析，发现精神分裂症和双相情感障碍患者前额叶皮层DARPP-32蛋白水平显著降低，提示其与认知功能障碍的关联(*Biological Psychiatry*, 2012)。
---
**备注**：若需具体文献来源或更多信息，建议通过PubMed或Google Scholar以“PPP1R1B antibody”或“DARPP-32 antibody”为关键词检索最新研究。部分研究可能侧重抗体应用(如检测蛋白表达、定位或翻译后修饰)，而非抗体开发本身。
PPP1R1B (Protein Phosphatase 1 Regulatory Inhibitor Subunit 1B), also known as DARPP-32 (Dopamine and cAMP-Regulated Phosphoprotein 32 kDa), is a critical signaling molecule in dopamine-mediated neurotransmission. It functions as a key integrator of dopamine and glutamate signaling pathways in the brain, particularly within striatal neurons. PPP1R1B acts as a dual-function regulator: when phosphorylated at Thr34 by protein kinase A (PKA), it inhibits protein phosphatase 1 (PP1), amplifying downstream kinase signaling (e.g., ERK, AKT), while phosphorylation at Thr75 converts it into an inhibitor of PKA. This dynamic regulation influences synaptic plasticity, reward processing, and motor control.
Antibodies targeting PPP1R1B are essential tools for studying its expression, post-translational modifications, and subcellular localization. They are widely used in neuroscience research to investigate neuropsychiatric disorders (e.g., schizophrenia, addiction) and neurodegenerative conditions linked to dopaminergic dysfunction. Commercially available antibodies include monoclonal and polyclonal variants validated for techniques like Western blotting, immunohistochemistry, and immunofluorescence. Some epitope-specific antibodies distinguish phosphorylation states (e.g., pThr34 vs. pThr75), enabling functional studies of dopamine signaling dynamics. Recent studies also explore PPP1R1B's role in cancers, as abnormal expression correlates with tumor progression in certain carcinomas. Proper validation (e.g., knockout controls) is crucial due to homology with other PP1 regulatory subunits.
×
